



Medicine Supply Notification

MSN/2025/052

Admelog® (insulin lispro) 100units/ml solution for injection 3ml cartridges

Admelog® (insulin lispro) 100units/ml solution for injection 3ml pre-filled pens

Admelog® (insulin lispro) 100units/ml solution for injection 10ml vials

Tier 2 – medium impact*

Date of issue: 18/09/2025

Link: [Medicines Supply Tool](#)

Summary

- Admelog® (insulin lispro) 100 units/ml solution for injection cartridges, pre-filled pens and vials are being discontinued with supplies anticipated to be exhausted by mid-March 2026, late March 2026 and mid-June 2026, respectively.
- Humalog® (insulin lispro) 100units/ml solution for injection cartridges, KwikPens® and vials remain available and can support increased demand.

Actions Required

Clinicians should not initiate new patients on Admelog®, which is a biosimilar insulin product.

Review existing patients and consider switching to the originator insulin product, Humalog® 100units/ml solution for injection, which can fully support the increased demand.

When switching to a Humalog® product:

- ensure all patients are informed of the reason for the switch, establish whether additional support is required with administration, and reassure them that they are receiving the same type of insulin, but they may initially need to check blood glucose levels more closely and have their dose adjusted if required;
- provide patients with training on the use of their new insulin preparation if required (see Supporting information), including signposting to training resources, and
- where a patient has been prescribed Humalog® cartridges, prescribe a HumaPen® SAVVIO® reusable pen and BD pen needles.

If the above options are not considered appropriate, advice should be sought from the diabetes team on use of other insulin products.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Admelog® (insulin lispro) is a biosimilar of the rapid-acting insulin Humalog®. A switch to Humalog® on a dose for dose basis can be considered in patients with stable/good glucose control who are not experiencing hypoglycaemic episodes, with close monitoring of blood glucose after the switch, and dose titrated if necessary. Dosing of Humalog® should be individualised for less stable patients.

Pen devices

- Admelog® pre-filled pens dial up insulin in 1-unit increments allowing the delivery of 1-80 units in a single injection
- Admelog® 100 units/ml in cartridges are used with the following pens: JuniorSTAR® which delivers 1-30 units in 0.5-unit dose increments, Tactipen® which delivers 1-60 units in 1-unit dose increments, and AllStar® and AllStar® PRO which all deliver 1-80 units of insulin lispro in 1-unit dose increments
- Humalog® KwikPens® are pre-filled disposable pens that dial up insulin in 1-unit increments allowing the delivery of 1 to 60 units in a single injection
- Humalog® 3ml cartridges are compatible with the HumaPen® SAVVIO® reusable pen which dials up insulin in 1-unit increments allowing the delivery of 1 to 60 units in a single injection
- For doses of >60 units delivered from Humalog® KwikPens® or cartridges (via a HumaPen® SAVVIO® reusable pen), multiple injections will be needed
- The HumaPen® SAVVIO® reusable pen and Humalog® KwikPens® are suitable for use with BD pen needles

Links to further information

[BNF Insulin](#)

[BNF Insulin preparations](#)

[SmPC Admelog®](#)

[SmPC Humalog®](#)

[User manual: KwikPen® pre-filled insulin pen](#)

[HumaPen® SAVVIO: instructions for use](#)

[NICE guidance: Type 1 diabetes in adults \(insulin therapy\)](#)

[NICE CKS- Insulin therapy in type 1 diabetes](#)

[NICE CKS- Insulin therapy in type 2 diabetes](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.